Spruce Biosciences to wind down investment for genetic disorder drug
10/12/2024 21:11
Dec 10 (Reuters) - Spruce Biosciences SPRB.O said on Tuesday it will wind down investments for its genetic disorder drug after it failed to meet the main goal in a mid-stage study. (Reporting by Sriparna Roy in Bengaluru; Editing by Krishna Chandra Eluri) ((Sriparna.Roy@thomsonreuters.com;))
Recent news on Spruce Biosciences
See all newsSpruce Biosciences, Inc. reports results for the quarter ended June 30 - Earnings Summary
Spruce Biosciences Q2 net loss widens on higher expenses
Spruce Biosciences, Inc. expected to post a loss of $5.80 a share - Earnings Preview
Brief: Spruce Biosciences Appoints Adrian Quartel, M.D., Ffpm, As Chief Medical Officer
Brief: Spruce Biosciences Announces Data Presentation At The 18Th International MPS Symposium